Mesoblast shares tank after US FDA rejects cell therapy for children

(Reuters) -The U.S. health regulator rejected Mesoblast’s cell therapy for children under 12 years of age for treating a type of complication that occurs after a stem cell or bone marrow transplant, sending its Australia-listed shares crashing about 58% on Friday. The U.S. Food and Drug Administration (FDA) required more data to support marketing approval…

Read More

Airbnb forecasts upbeat revenue as international travel rebounds

By Priyamvada C and Doyinsola Oladipo (Reuters) -Airbnb forecast third-quarter revenue above market estimates on Thursday, but industry fears of softening U.S. domestic demand sent the vacation rental firm’s shares down 1.2% in after-hours trading. The San Francisco-based company forecast quarterly revenue between $3.3 billion and $3.4 billion, ahead of analysts’ average estimate of $3.22…

Read More

China’s Zhengzhou city launches property support measures

BEIJING (Reuters) – China’s Zhengzhou city has launched measures to support its property market, including easing home resale restrictions, in what analysts said were the first such moves by a big city heeding signals from policymakers. The measures by the capital of China’s central Henan province included reductions on mortgage rates and down payment ratios,…

Read More

Florida effectively bans advanced psychology course over LGBTQ content – course developer

By Sharon Bernstein (Reuters) -Florida has told school superintendents that an Advanced Placement psychology course offered to high school students violates a new state law prohibiting instruction on sexual orientation and gender identity, the nonprofit that develops the courses said on Thursday. “The Florida Department of Education has effectively banned AP Psychology in the state,”…

Read More